#EULAR2024: Transition and patient outcomes

To update you on the exciting content presented at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, we have collated our social media coverage. Catch up with our live social media relating to transition, patient outcomes, and other key tweets, here.

Transition

CONGRESS #EULAR2024 | @DrMariola presented data on biomarkers of transition from PsO to PsA. Patients were selected if there was no exposure to biologic before rheumatological assessment. In the skin there is an increase in mReg DCs in lesional skin of patients at risk of PsA.… pic.twitter.com/N1l4aNHAzT

— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024

CONGRESS #EULAR2024 | POSTER: Sofia Ferreira Azevedo presented a poster on preventing PsA in patients with psoriasis. bDMARDs were found to reduce the risk for progression to PsA compared to other treatments. #psoriaticarthritis pic.twitter.com/6r31dgNBtg

— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024

CONGRESS #EULAR2024 | Dr. Beatriz Joven-Ibáñez presented data from a TRINETX global population study of transition risk from PsO to PsA with biologics. Assessed 1,175,000 patients with PsO. Incidence of PsA was higher in patients treated with TNFis vs ILis. #psoriasis… pic.twitter.com/Ct1wInDcDX

— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 12, 2024

Patient outcomes

CONGRESS #EULAR2024 | POSTER: Dr. Philip J. Mease presented a poster on data from the phase IV MOSAIC study. At Weeks 24 and 48, patients treated with apremilast showed significant improvement in PROs, MRI (of the hand), and clinical outcomes. MRI can be a valuable tool for… pic.twitter.com/KnRjmEjBY5

— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024

CONGRESS #EULAR2024 | POSTER: Pasal H.P. de Jong presented a poster on the association between depression and anxiety and achieving remission in PsA. Having depression or anxiety was associated with more tender joints and increased pain, and these patients were less likely to… pic.twitter.com/yN2ZKnS7hV

— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024

Other

CONGRESS #EULAR2024 | Dr. Alan Kivitz presented the safety and efficacy of zasocitinib (TAK-279) over 12 weeks. TEAEs were highest in the 30mg group vs 15mg and 5mg. There were no TEAEs leading to death. Efficacy of zasocitinib was superior compared to placebo. #psoriasis… pic.twitter.com/Hmb5LoYPbQ

— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 13, 2024

CONGRESS #EULAR2024 | Prof. Adrian Ciurea presented data on resolution of joint swelling in different locations with TNFis in PsA. N = 1729. After TNFi, the elbow and shoulder saw higher resolution compared to the wrist. Differences did not depend on the size of the joint.… pic.twitter.com/2xXYC6xN4H

— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 12, 2024

CONGRESS #EULAR2024 | Dr Erik Lubberts discussed the BRIGHT concept that intestinal microbiota shapes immune response in PsA. T cells are linked to gut inflammation and disease activity. Findings suggest there is potentially higher inflammation axial and polyarthritis PsA… pic.twitter.com/S9e8Wdbyhr

— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) June 14, 2024